FDA issues warning letter to Amazon

Nov. 16, 2023
The FDA issued a warning letter on Nov. 13 to Amazon regarding the sale of unapproved eye drops

On Nov. 13, the FDA issued a warning letter to Amazon.com, Inc. for the firm’s distribution of “Similasan Pink Eye Relief,” “The Goodbye Company Pink Eye,” “Can-C Eye Drops,” “Optique 1 Eye Drops,” “OcluMed Eye Drops,” “TRP Natural Eyes Floaters Relief” and “Manzanilla Sophia Chamomile Herbal Eye Drops” products.

These products are not generally recognized as safe and effective for their claimed uses, including temporary relief of minor eye symptoms such as excessive watery (clear) discharge, sensation of grittiness, redness and burning, or pink eye. Therefore, these products are categorized as “new drugs” under the Federal Food, Drug & Cosmetic Act. Ophthalmic drug products are especially concerning from a public health perspective. Products intended for use in the eyes generally pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses. 

FDA has the warning letter.

ID 204561283 | Abstract © Dimitris Barletis | Dreamstime.com
dreamstime_xl_204561283
ID 366090882 © Zhanna Hapanovich | Dreamstime.com
dreamstime_xl_366090882
ID 179810040 © Josepalbert13 | Dreamstime.com
cdc_3
ID 150983874 © Adonis1969 | Dreamstime.com
dreamstime_xl_150983874
ID 241576013 © Josepalbert13 | Dreamstime.com
cms_2